Events

Participate in our Events

Members of APCaRI are involved in a wide range of translational, clinical and discovery research events such as scientific conferences and meetings. These meetings help keep us at the forefront of scientific discovery and application. Our scientists and trainees present posters and give talks helping stimulate interest in the overall program by national and international collaborations

We are also invested in the local and provincial community, reaching out to Albertans through many events tied to fundraising and prostate cancer awareness. We work alongside organizations like the Alberta Cancer foundation, Prostate Cancer Canada, MotorCycle Ride for Dad and Movember to help stimulate fundraising as well as provide the donors with a direct link and people to answer questions about where their donated dollars actually go.

The staff at the Alberta Cancer Foundation have harnessed our group for many events since we have arrived in Alberta.

 

Alberta Ride to Conquer Cancer

The Enbridge Ride to Conquer Cancer® During this bold cycling journey, members of the APCaRI team will ride for two whole days along the majestic Rockies! Our mission is clear – a cancer-free future. The money is raised for the Alberta Cancer Foundation and will directly support patients and families at the Tom Baker Cancer Centre in Calgary, the Cross Cancer Institute in Edmonton and 15 cancer centres throughout Alberta.

The Alberta Cancer Foundation provides funding to a team of top doctors and scientists whose search for new discoveries and improved patient outcomes will have a real impact in your community, across Canada, and around the world.

4 members of the Lewis Lab will participate in this event!

Dr. Nawaid Usmani and team receive funding for their PRIME study!

The PRIME Study – Prevention and Intervention for MEtabolic syndrome:

Androgen deprivation therapy (ADT), and newer manipulations of androgen receptor signaling have improved outcomes for advanced prostate cancer (PCa) patients.  The toxicities of ADT are many, including an increased risk of developing metabolic syndrome (MS; defined as at least 3 of: hyperglycemia; abdominal obesity; hypertriglyceridemia; reduced HDL cholesterol; and/or hypertension). MS is associated with an increased risk of diabetes, cardiovascular disease mortality, stroke mortality, and all-cause mortality.  The prevalence of MS in men receiving ADT is at least 50% and contributes to decreased quality of life and increased non-cancer-related mortality.  Metformin holds promise as a countermeasure to MS development, and also has been shown to suppress PCa growth in pre-clinical models.

We hypothesize that the addition of metformin to ADT will reduce the rates of MS in men with advanced PCa, diminishing important toxicities of a therapy universally used in advanced disease.

We propose a double-blind, randomized phase III study of metformin or placebo in men with PCa starting intermittent ADT. The primary endpoint is the difference in MS rates at 1 year.  Other aims include evaluation of the influence of metformin on: individual MS components at additional time points; mean serum insulin levels and measures of insulin resistance; weight and quality of life.

A finding that metformin reduces MS incidence and/or has other benefits would change practice, as it would provide a practical and inexpensive strategy to reduce toxicity of an intervention employed in most men with advanced PCa.

- Catalina Vasquez

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.